Ajovy bags NICE approval
The anti-CGRP preventive therapy is the first of-its-kind to be recommended by NICE.
Read More
Tag: anti-CGRP
Teva’s anti-CGRP drug Ajovy cleared for migraine prevention
US regulators have approved Teva’s Ajovy for the preventative treatment of migraine in adults.
Read More
Teva’s anti-CGRP drug under review for migraine
US regulators are now reviewing Teva Pharmaceutical’s experimental anti-CGRP therapy fremanezumab for the preventive treatment of migraine, and have also granted the drug a fast track designation for the prevention of cluster headache.
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
